title: MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans.
abstract: OBJECTIVE
  Insufficient blood supply to the heart results in ischemic injury manifested clinically as myocardial infarction (MI). Following ischemia, inflammation is provoked and related to the clinical outcomes. A recent basic science study indicates that complement factor MASP-2 plays an important role in animal models of ischemia/reperfusion injury. We investigated the role of MASP-2 in human acute myocardial ischemia in two clinical settings: (1) Acute MI, and (2) Open heart surgery.
  
  
  METHODS
  A total of 187 human subjects were enrolled in this study, including 50 healthy individuals, 27 patients who were diagnosed of coronary artery disease (CAD) but without acute MI, 29 patients with acute MI referred for coronary angiography, and 81 cardiac surgery patients with surgically-induced global heart ischemia. Circulating MASP-2 levels were measured by ELISA.
  
  
  RESULTS
  MASP-2 levels in the peripheral circulation were significantly reduced in MI patients compared with those of healthy individuals or of CAD patients without acute MI. The hypothesis that MASP-2 was activated during acute myocardial ischemia was evaluated in cardiac patients undergoing surgically-induced global heart ischemia. MASP-2 was found to be significantly reduced in the coronary circulation of such patients, and the reduction of MASP-2 levels correlated independently with the increase of the myocardial necrosis marker, cardiac troponin I.
  
  
  CONCLUSIONS
  These results indicate an involvement of MASP-2 in ischemia-related necrotic myocardial injury in humans.
authors.affiliation: Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY, USA. ming.zhang@downstate.edu
authors.forename: Ming
authors.initials: M
authors.lastname: Zhang
authors.forename: Yunfang Joan
authors.initials: YJ
authors.lastname: Hou
authors.forename: Erdal
authors.initials: E
authors.lastname: Cavusoglu
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Lee
authors.forename: Rudi
authors.initials: R
authors.lastname: Steffensen
authors.forename: Liming
authors.initials: L
authors.lastname: Yang
authors.forename: Daniel
authors.initials: D
authors.lastname: Bashari
authors.forename: Jose
authors.initials: J
authors.lastname: Villamil
authors.forename: Motaz
authors.initials: M
authors.lastname: Moussa
authors.forename: George
authors.initials: G
authors.lastname: Fernaine
authors.forename: Jens C
authors.initials: JC
authors.lastname: Jensenius
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Marmur
authors.forename: Wilson
authors.initials: W
authors.lastname: Ko
authors.forename: Ketan
authors.initials: K
authors.lastname: Shevde
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D004789:Enzyme Activation / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D050606:Mannose-Binding Protein-Associated Serine Proteases / Q000378:metabolism*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology*; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology*; D009336:Necrosis; D055815:Young Adult
chemical_list: D015415:Biomarkers; C105296:MASP2 protein, human; D050606:Mannose-Binding Protein-Associated Serine Proteases